We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
- Authors
Long, J.; Tao Qu; Pan, X. F.; Tang, X.; Wan, H. H.; Qiu, P.; Yan-Hua Xu; Qu, Tao; Xu, Yan-Hua
- Abstract
<bold>Objective: </bold>To investigate the correlation between the expression of programmed death 1 (PD-1) and PD ligand-1 (PD-L1) in hepatocellular carcinoma (HCC) and clinical parameters.<bold>Materials and Methods: </bold>The study comprised tumor sections from 45 HCC patients treated with curative resection, which were evaluated for PD-1 and PD-L1 protein expression by immunohistochemistry.<bold>Results: </bold>PD-1 and PD-L1 expression was increased in cancers compared to adjacent normal tissues, with a positive rate of 37.78% (17/45) and 62.22% (28/45), respectively, which was positively correlated with the tumor stage and lymph node metastasis, negatively with postoperative prognosis. PD-1 positivity was most frequently observed in stromal tumor-infiltrating lymphocytes. The number of PD-1 positive lymphocyte was correlated with PD-L1 positive expression.<bold>Conclusion: </bold>PD-L1 and PD-1 are overexpressed in HCC tissues. PD-L1 expression plays a critical role in the pathogenesis of human HCC, suggesting that it might be used as a new biomarker to predict the disease progression and prognosis.
- Subjects
LIVER cancer; IMMUNOHISTOCHEMISTRY; SURGICAL excision; LYMPHOCYTES; LYMPH nodes; LIVER surgery; ANTIGENS; HEPATOCELLULAR carcinoma; LIVER; LIVER tumors; LONGITUDINAL method; METASTASIS; PROGNOSIS; SURVIVAL analysis (Biometry); TUMOR classification; DISEASE progression
- Publication
Journal of Cancer Research & Therapeutics, 2018, Vol 14, pS1188
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/0973-1482.204850